S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)

MetLife (MET) Stock Forecast & Price Target

$69.14
+0.57 (+0.83%)
(As of 02/27/2024 ET)

MetLife Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$77.23
11.70% Upside
High Forecast$83.00
Average Forecast$77.23
Low Forecast$71.00
TypeCurrent Forecast
2/27/23 to 2/27/24
1 Month Ago
1/28/23 to 1/28/24
3 Months Ago
11/29/22 to 11/29/23
1 Year Ago
2/27/22 to 2/27/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$77.23$77.62$75.45$80.36
Predicted Upside11.70% Upside23.01% Upside22.77% Upside17.05% Upside
Get MetLife Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MET and its competitors with MarketBeat's FREE daily newsletter.


MET Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

MetLife Stock vs. The Competition

TypeMetLifeFinance CompaniesS&P 500
Consensus Rating Score
2.92
2.42
2.48
Consensus RatingModerate BuyHoldHold
Predicted Upside11.73% Upside74.88% Upside7.86% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/6/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$85.00 ➝ $83.00+25.28%
2/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$87.00 ➝ $82.00+24.05%
1/8/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$70.00 ➝ $80.00+16.08%
12/7/2023Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$79.00 ➝ $77.00+21.28%
11/17/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$71.00+14.46%
11/2/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$79.00 ➝ $80.00+33.31%
10/6/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$85.00 ➝ $82.00+36.05%
10/4/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$71.00+18.33%
9/13/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$58.00 ➝ $72.00+12.87%
8/14/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$70.00 ➝ $77.00+20.97%
8/9/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$76.00 ➝ $81.00+27.56%
8/4/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$70.00 ➝ $74.00+14.14%
4/5/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$82.00 ➝ $74.00+29.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:50 PM ET.












MET Price Target - Frequently Asked Questions

What is MetLife's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for MetLife stock is Moderate Buy based on the current 1 hold rating and 12 buy ratings for MET. The average twelve-month price prediction for MetLife is $77.23 with a high price target of $83.00 and a low price target of $71.00. Learn more on MET's analyst rating history.

Do Wall Street analysts like MetLife more than its competitors?

Analysts like MetLife more than other Finance companies. The consensus rating for MetLife is Moderate Buy while the average consensus rating for finance companies is Hold. Learn more on how MET compares to other companies.

Is MetLife being upgraded by Wall Street analysts?

Over the previous 90 days, MetLife's stock had 1 upgrade by analysts.

Does MetLife's stock price have much upside?

According to analysts, MetLife's stock has a predicted upside of 22.46% based on their 12-month stock forecasts.

What analysts cover MetLife?

MetLife has been rated by Keefe, Bruyette & Woods, The Goldman Sachs Group, UBS Group, and Wells Fargo & Company in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:MET) was last updated on 2/27/2024 by MarketBeat.com Staff